IL88344A - Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages - Google Patents

Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages

Info

Publication number: IL88344A
Authority: IL; Israel
Prior art keywords: composition; bone; csf; administration; stimulators
Prior art date: 1987-11-12

Application number

IL8834488A

Other languages

English (en)

Hebrew (he)

Other versions

IL88344A0 (en

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-12

Filing date

1988-11-10

Publication date

1994-06-24

1988-11-10 Application filed by Schering Corp filed Critical Schering Corp

1989-06-30 Publication of IL88344A0 publication Critical patent/IL88344A0/xx

1994-06-24 Publication of IL88344A publication Critical patent/IL88344A/en

Links

102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title claims description 51
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title claims description 51
230000011164 ossification Effects 0.000 title claims description 22
230000001133 acceleration Effects 0.000 title description 4
239000000203 mixture Substances 0.000 claims description 27
238000000034 method Methods 0.000 claims description 21
208000010392 Bone Fractures Diseases 0.000 claims description 20
206010020649 Hyperkeratosis Diseases 0.000 claims description 17
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 12
241000124008 Mammalia Species 0.000 claims description 12
230000010072 bone remodeling Effects 0.000 claims description 12
102000046157 human CSF2 Human genes 0.000 claims description 12
230000008569 process Effects 0.000 claims description 12
230000015572 biosynthetic process Effects 0.000 claims description 10
102000004169 proteins and genes Human genes 0.000 claims description 9
108090000623 proteins and genes Proteins 0.000 claims description 9
208000001132 Osteoporosis Diseases 0.000 claims description 8
230000037396 body weight Effects 0.000 claims description 7
229940078581 Bone resorption inhibitor Drugs 0.000 claims description 6
239000002617 bone density conservation agent Substances 0.000 claims description 6
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 5
230000003262 anti-osteoporosis Effects 0.000 claims description 4
238000007918 intramuscular administration Methods 0.000 claims description 4
238000007920 subcutaneous administration Methods 0.000 claims description 4
230000000699 topical effect Effects 0.000 claims description 4
102000003982 Parathyroid hormone Human genes 0.000 claims description 3
108090000445 Parathyroid hormone Proteins 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
229940094443 oxytocics prostaglandins Drugs 0.000 claims description 3
239000000199 parathyroid hormone Substances 0.000 claims description 3
229960001319 parathyroid hormone Drugs 0.000 claims description 3
150000003180 prostaglandins Chemical class 0.000 claims description 3
239000011775 sodium fluoride Substances 0.000 claims description 3
235000013024 sodium fluoride Nutrition 0.000 claims description 3
229960000414 sodium fluoride Drugs 0.000 claims description 3
102000055006 Calcitonin Human genes 0.000 claims description 2
108060001064 Calcitonin Proteins 0.000 claims description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
229960004015 calcitonin Drugs 0.000 claims description 2
239000003862 glucocorticoid Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000007910 systemic administration Methods 0.000 claims description 2
229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims 2
210000000988 bone and bone Anatomy 0.000 description 25
206010017076 Fracture Diseases 0.000 description 23
210000004027 cell Anatomy 0.000 description 15
230000000694 effects Effects 0.000 description 11
238000011282 treatment Methods 0.000 description 10
230000001054 cortical effect Effects 0.000 description 9
238000007634 remodeling Methods 0.000 description 9
235000018102 proteins Nutrition 0.000 description 8
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
208000006386 Bone Resorption Diseases 0.000 description 5
102000038566 DCAFs Human genes 0.000 description 5
108091007824 DCAFs Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
150000001413 amino acids Chemical group 0.000 description 5
230000024279 bone resorption Effects 0.000 description 5
210000001564 haversian system Anatomy 0.000 description 5
239000004098 Tetracycline Substances 0.000 description 4
230000037213 diet Effects 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000001009 osteoporotic effect Effects 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
229960002180 tetracycline Drugs 0.000 description 4
229930101283 tetracycline Natural products 0.000 description 4
235000019364 tetracycline Nutrition 0.000 description 4
150000003522 tetracyclines Chemical class 0.000 description 4
208000029725 Metabolic bone disease Diseases 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010049088 Osteopenia Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000002805 bone matrix Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000011161 development Methods 0.000 description 2
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
210000002901 mesenchymal stem cell Anatomy 0.000 description 2
230000000921 morphogenic effect Effects 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
208000025962 Crush injury Diseases 0.000 description 1
206010017088 Fracture nonunion Diseases 0.000 description 1
241000282620 Hylobates sp. Species 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
208000001164 Osteoporotic Fractures Diseases 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
208000013201 Stress fracture Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000007470 bone biopsy Methods 0.000 description 1
229940112869 bone morphogenetic protein Drugs 0.000 description 1
230000008416 bone turnover Effects 0.000 description 1
229940069978 calcium supplement Drugs 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002436 femur neck Anatomy 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
238000007491 morphometric analysis Methods 0.000 description 1
230000003562 morphometric effect Effects 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
230000001582 osteoblastic effect Effects 0.000 description 1
230000001599 osteoclastic effect Effects 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
238000007747 plating Methods 0.000 description 1
238000001907 polarising light microscopy Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000007306 turnover Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL8834488A 1987-11-12 1988-11-10 Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages IL88344A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11961187A	1987-11-12	1987-11-12

Publications (2)

Publication Number	Publication Date
IL88344A0 IL88344A0 (en)	1989-06-30
IL88344A true IL88344A (en)	1994-06-24

Family

ID=22385326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8834488A IL88344A (en)	1987-11-12	1988-11-10	Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages

Country Status (6)

Country	Link
EP (2)	EP0318184A1 (ja)
JP (1)	JPH0649655B2 (ja)
AU (1)	AU638204B2 (ja)
DK (1)	DK116390D0 (ja)
IL (1)	IL88344A (ja)
WO (1)	WO1989004173A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69001686T2 (de) *	1989-01-30	1993-09-02	Schering Corp	Behandlung von leukozytstoerungen mit gm-csf.
NZ236618A (en) *	1990-01-03	1997-06-24	Ciba Geigy Ag	Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5206023A (en) *	1991-01-31	1993-04-27	Robert F. Shaw	Method and compositions for the treatment and repair of defects or lesions in cartilage
US5118667A (en) *	1991-05-03	1992-06-02	Celtrix Pharmaceuticals, Inc.	Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH0517367A (ja) *	1991-07-08	1993-01-26	Green Cross Corp:The	骨粗鬆症治療剤
US5270300A (en) *	1991-09-06	1993-12-14	Robert Francis Shaw	Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
DK0988871T3 (da) *	1991-12-18	2004-05-24	Icu Medical Inc	Fremgangsmåde til overføring af fluid
TW267102B (ja)	1992-03-13	1996-01-01	Ciba Geigy
SE9702401D0 (sv)	1997-06-19	1997-06-19	Astra Ab	Pharmaceutical use
EP0891779A1 (de) *	1997-06-19	1999-01-20	Roche Diagnostics GmbH	Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
JP4709440B2 (ja) *	2001-08-20	2011-06-22	高山産業株式会社	通気路形成用のスペーサーおよびそのスペーサーを用いた壁体の通気路形成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR893138A (fr) *	1940-04-05	1944-05-31		Procédé de préparation d'un produit destiné à guérir les fractures des os
IL78342A (en) *	1985-04-04	1991-06-10	Gen Hospital Corp	Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5078996A (en) *	1985-08-16	1992-01-07	Immunex Corporation	Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
DE3545568A1 (de) *	1985-12-21	1987-07-16	Hoechst Ag	Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
AU626530B2 (en) *	1987-07-17	1992-08-06	Schering Biotech Corporation	Human granulocyte-macrophage colony stimulating factor and muteins thereof

1988
- 1988-11-10 EP EP88310594A patent/EP0318184A1/en not_active Withdrawn
- 1988-11-10 IL IL8834488A patent/IL88344A/en not_active IP Right Cessation
- 1988-11-10 AU AU27103/88A patent/AU638204B2/en not_active Ceased
- 1988-11-10 JP JP63509410A patent/JPH0649655B2/ja not_active Expired - Lifetime
- 1988-11-10 WO PCT/US1988/003922 patent/WO1989004173A1/en not_active Ceased
- 1988-11-10 EP EP88910226A patent/EP0386109A1/en active Pending
1990
- 1990-05-10 DK DK116390A patent/DK116390D0/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0386109A1 (en)	1990-09-12
WO1989004173A1 (en)	1989-05-18
JPH0649655B2 (ja)	1994-06-29
IL88344A0 (en)	1989-06-30
DK116390A (da)	1990-05-10
AU638204B2 (en)	1993-06-24
DK116390D0 (da)	1990-05-10
AU2710388A (en)	1989-06-01
JPH02502642A (ja)	1990-08-23
EP0318184A1 (en)	1989-05-31

Legal Events

Date	Code	Title	Description
1999-11-30	RH	Patent void

Publication	Publication Date	Title
Nakamura et al.	1998	Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture
Hollinger et al.	2008	Recombinant human platelet-derived growth factor: biology and clinical applications
Wang et al.	2009	Controlled-release of rhBMP-2 carriers in the regeneration of osteonecrotic bone
Al‐Zube et al.	2009	Recombinant human platelet‐derived growth factor BB (rhPDGF‐BB) and beta‐tricalcium phosphate/collagen matrix enhance fracture healing in a diabetic rat model
Guizzardi et al.	2003	Polydeoxyribonucleotide (PDRN) promotes human osteoblast proliferation: a new proposal for bone tissue repair
Cho et al.	2007	Expression and role of interleukin-6 in distraction osteogenesis
CN101678067A (zh)	2010-03-24	Nell-1增强的骨矿化作用
Lucas et al.	1997	Stimulation of systemic bone formation induced by experimental blood loss.
US7622438B1 (en)	2009-11-24	Protein formulation for promoting hard tissue formation
IL88344A (en)	1994-06-24	Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages
IE861422L (en)	1986-11-30	Use of ifn - x for inhibiting bone degradation
JP2007537281A (ja)	2007-12-20	骨形成の促進方法と維持
CN104379171A (zh)	2015-02-25	骨修复促进剂
EP1313440B1 (en)	2008-07-16	Dental products comprising bone growth enhancing peptide
EP2268301B1 (en)	2020-02-26	Erythropoietin and fibronectin compositions for bone regeneration
Feng et al.	2021	Small blood stem cells for enhancing early osseointegration formation on dental implants: a human phase I safety study
Bail et al.	2002	Recombinant species-specific growth hormone increases hard callus formation in distraction osteogenesis
Mosekilde et al.	1993	The effects of growth hormone on fracture healing in rats: a histological description
Lawrence et al.	2006	Effect of daily parathyroid hormone (1–34) on lumbar fusion in a rat model
Schneider et al.	2003	The anabolic effects of vitamin D-binding protein-macrophage activating factor (DBP-MAF) and a novel small peptide on bone
Bail et al.	2003	Systemic application of growth hormone enhances the early healing phase of osteochondral defects—a preliminary study in micropigs
WO2015057836A2 (en)	2015-04-23	Bone anabolic parathyroid hormone and parathyroid hormone related-protein analogs
Drakopoulos et al.	2021	Off-label use of teriparatide in spine
Morshed et al.	2017	Fracture healing
Chunxiao et al.	2017	Pharmacological effects of a recombinant hPTH (1− 34) derived peptide on ovariectomized rats